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after starting infliximab (November 2013), the patient com-
plained of inflammatory symmetrical polyarthralgia (knee, 
shoulder, elbow, and wrist) without synovitis, which started 
every week before the administration of infliximab. Resolu-
tion of symptoms was observed after each infliximab infu-
sion. In July 2014, the autoantibody re-evaluation showed 
positive ANA with a homogeneous pattern with a titer of 1: 
 640, weak positive anti-dsDNA (30.2), and positive anti-his-
tone with C3 decreased (80.3). She was then diagnosed with 
lupus induced by infliximab and initiated hydroxychloro-
quine 400 mg. Infliximab was suspended. On re-evaluation, 
the erythrocyte sedimentation rate was 25 mm/h (1st hour), 
C-reactive protein 0.5 mg/dL (previously erythrocyte sedi-
mentation rate 15 mm/h and C-reactive protein 1.2 mg/dL), 
and endoscopically, the mucosa was scarred, with some at-
rophy and scarce mucus in the lower rectum. About 10 
months after discontinuation of infliximab, repeated auto-
antibodies proved all negative, keeping only low C3 (87). The 
patient also reported complete resolution of the arthralgia. 
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 Abstract 
 We report the case of a 48-year-old, leukodermic female di-
agnosed with ulcerative proctitis for 4 years and latent tu-
berculosis. She was allergic to salicylates and had a minor 
allergic reaction to infliximab (rash, vertigo, and headache). 
Thereafter, she started azathioprine (2.5 mg/kg/day). She 
maintained intravenous infliximab, together with prophy-
laxis with clemastine and hydrocortisone, due to the steroid-
dependent proctitis. The therapy was continued every 8 
weeks with anti-tumor necrosis factor for about 3 years. The 
analytical evaluation when she was diagnosed with ulcer-
ative proctitis (February 2011) showed negative antinuclear 
antibodies (ANA), double-stranded-DNA antibodies (anti-
dsDNA), antineutrophil cytoplasmic antibodies and anti-
 Saccharomyces cerevisiae antibodies, and a positive outer 
membrane protein antibody. About 2 years and 6 months 
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 Lupus Induzido por Infliximab: Relato de um Caso 
 Palavras Chave 
 Doenças inflamatórias intestinais, tratamento · Factor de 
necrose tumoral alfa, uso terapêutico · Infliximab, uso 
terapêutico · Lupus eritematoso, sistémico/induzido 
quimicamente 
 Resumo 
 Relato do caso de uma mulher, 48 anos, leucodérmica, 
com o diagnóstico de proctite ulcerosa com 4 anos de 
evolução e tuberculose latente. Alérgica aos salicilatos e 
com reacção alérgica minor ao infliximab (rash, cefaleia e 
vertigem), iniciou azatioprina (2,5 mg/kg/dia) apenas 
após a reacção alérgica. Manteve infliximab com profi-
laxia endovenosa com clemastina e hidrocortisona dada 
a cortico-depedência da proctite. A terapêutica com anti-
TNF foi mantida de 8 em 8 semanas durante cerca de 3 
anos. Na avaliação analítica aquando o diagnóstico da 
doença inflamatória intestinal (Fev 2011) apresentava 
ANA, anti-dsDNA, ANCAs e ASCA negativos com anti-
OMP positivo. Cerca de 2 anos e meio após o início de
infliximab (Nov 2013), iniciou quadro de poliartralgia in-
flamatória simétrica (joelhos, ombros, cotovelos e pu-
nhos) sem sinovite com início regular na semana prévia à 
admnistração programada de infliximab e resolução após 
a infusão endovenosa. Em Julho de 2014, apresenta ANA 
positivos com padrão homogéneo com título de 1/640, 
anti-dsDNA equívoco (30.2), anti-histonas positivo com 
C3 diminuído (80.3). Foi diagnosticada com lupus erite-
matoso sistémico induzido por infliximab e iniciou hidro-
xicloroquina 400 mg. O infliximab foi suspenso. Na reava-
liação da doença, destaca-se VS 25 mm/h (1ª hora), PCR 
0,5 mg/dL (previamente VS 15 e PCR 0.6) e endoscopica-
mente mucosa cicatrizada, com alguma atrofia e escasso 
muco no recto baixo. Cerca de 10 meses após a suspensão 
do infliximab, repetiu auto-anticorpos que se revelaram 
todos negativos, mantendo apenas o C3 baixo (87). Veri-
ficou-se ainda resolução completa das queixas articula-
res.  © 2016 Sociedade Portuguesa de Gastrenterologia
Publicado por S. Karger AG, Basel 
 Introduction 
 Tumor necrosis factor alpha blocker therapies (anti-
TNF) are widely used in the treatment of inflammatory 
bowel disease (IBD) and in a rapidly expanding number 
of rheumatic and immune-mediated diseases. Its use has 
been associated with the development of anti-TNF anti-
bodies, autoantibodies, and, paradoxically, with autoim-
mune diseases  [1] . The induction of autoantibodies is fre-
quent, but the development of an autoimmune disease 
such as drug-induced lupus (DIL) is a rare event  [1, 2] .
 DIL is a clinical syndrome with features similar to sys-
temic lupus erythematosus (SLE), but with some differ-
ences in laboratory and clinical findings  [3–5] . The diag-
nosis of lupus-induced infliximab should be considered in 
a patient who develops antinuclear antibodies (ANA) and 
presents with at least 1 clinical criterion for lupus (arthri-
tis, serositis, or rash)  [5] . Concomitant immunosuppres-
sion is known to reduce autoantibody formation, and in 
most DIL cases, the suspension of anti-TNF leads to the 
resolution of the condition  [2, 5] . In a large series of 72 
cases of lupus induced by anti-TNF, the signs and symp-
toms resolved in 71 patients  [6] . Some cases might require 
specific therapy while symptoms prevail  [7] . The time to 
clear the autoantibodies is superior to the clinical remis-
sion and in some patients may take more than 1 year  [8] .
 According to post-marketing studies, DIL has an esti-
mated prevalence of 0.19–0.22% for infliximab, 0.18% for 
etanercept, and 0.10% for adalimumab. Nevertheless, in 
randomized controlled trials, the prevalence is higher, 
reaching 0.78%  [7] .
 Clinical Findings 
 The subject of this report is a 48-year-old, leukodermic 
female born and resident in Funchal, Madeira Island. She 
was medicated with amiloride 5 mg plus hydrochloro-
thiazide 50 mg once daily for arterial hypertension. Five 
years ago, she had a left oophorectomy for an ovarian 
cyst. She was allergic to acetylsalicylic acid and ibuprofen. 
She denied alcohol consumption, tobacco, or drug abuse. 
No relevant family history was found.
 In January 2011, the patient was referred to the gastro-
enterology department with a 2-month history of chron-
ic diarrhea (4–5 soft stools per day). Three weeks before, 
rectal bleeding, urgency, and tenesmus had begun, and 1 
week before, the passage of mucus had occurred.
 A total colonoscopy with ileoscopy revealed a normal 
terminal ileum and colonic mucosa. In the rectum, up 
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to 15 cm from the anal margin, hyperemic mucosa with 
petechiae, great friability, and mucus was found. The en-
doscopic appearance was compatible with ulcerative 
proctitis Mayo endoscopic subscore 2. Histologically, 
the ileum had no abnormalities, and the rectum revealed 
distortion of the glandular architecture and mucin de-
pletion with a chronic inflammatory process with signs 
of activity and ulceration. There were numerous crypt 
abscesses, and in the lamina propria, xanthomatous 
macrophages were negative for periodic acid-Schiff 
stain, periodic acid-Schiff diastase stain, and Ziehl-
Neelsen stain.
 The analytical evaluation at this time showed negative 
ANA, double-stranded-DNA antibodies (anti-dsDNA), 
perinuclear antineutrophil cytoplasmic antibodies (AN-
CA), cytoplasmic-ANCA, and anti- Saccharomyces cere-
visiae antibodies (ASCA, IgG, and IgA). There was a pos-
itive outer membrane protein antibody of 42.5 (reference 
range [RR] <20).
 She was prescribed mesalazine 1 g suppositories once 
daily. Three days later, she developed an urticarial reac-
tion, and mesalazine was suspended; the urticaria rapidly 
subsided. She was then started on budesonide 2 mg ene-
mas once daily. Two months later, she maintained the 
symptoms and had more rectal bleeding. Prednisolone 40 
mg o.s. daily was initiated, and within 10 days, rectal 
bleeding, urgency, tenesmus, or passage of mucus disap-
peared, but she maintained diarrhea (4 soft bowel move-
ments per day). When prednisolone was weaned (at 10 
mg/day), the symptoms relapsed, and we decided to in-
troduce infliximab given that the patient was very symp-
tomatic with an impaired quality of life that conditioned 
labor absence. The objective at this time was a fast re-
sponse, and immunosuppressant was not added.
 The pre-infliximab screening revealed latent tubercu-
losis, and the patient was administered isoniazid 300 mg 
per day and 20 mg pyridoxine for 6 months. One month 
later, she started infliximab treatment, which included 
prophylaxis with hydroxyzine 25 mg o.s. and intravenous 
(i.v.) prednisolone 75 mg. The undergoing treatment for 
latent tuberculosis was a major conditioning factor for an 
early top-down approach.
 During the third infusion of infliximab, the patient 
complained of headache and vertigo, and a generalized 
rash was objectified. She was immediately medicated with 
metoclopramide i.v. and 80 mg of methylprednisolone 
i.v., with clinical improvement. The option of monother-
apy with infliximab was upgraded at this time (about 10 
weeks of treatment with isoniazid) to combined immu-
nosuppression with anti-TNF and an immunosuppres-
sant (accelerated step-care approach). Therefore, azathi-
oprine at 150 mg per day (2.5 mg/kg) was added with the 
objective of reducing anti-infliximab antibody formation, 
weighing carefully against the risk of a tuberculosis reac-
tivation. In view of the steroid-dependent colitis, it was 
decided to maintain infliximab therapy along with pro-
phylaxis with clemastine 2 mg i.v. and hydrocortisone 
300 mg i.v. No allergic reactions were observed during the 
following 3 years of therapy.
 Six months after the initiation of infliximab, the sig-
moidoscopy revealed abundant mucus, loss of the vascu-
lar pattern, and a slight friable mucosa in the last 15 cm 
of the rectum (Mayo subscore 1).
 Diagnostic Focus and Assessment 
 About 2 years and 6 months after starting infliximab 
(November 2013), the patient complained about malaise 
and inflammatory symmetrical polyarthralgia (knee, 
shoulder, elbow, and wrist) without objectifiable arthritis 
and with a regular start of the symptoms in the week pri-
or to the scheduled administration of infliximab and res-
olution of the complaints after the i.v. infusion.
 In July 2014, the autoantibody re-evaluation showed a 
positive ANA with a homogeneous pattern and a titer of 
1: 640, weak positive anti-dsDNA (30.2; RR <20), positive 
anti-histone, low C3 (80.3), and IgM 281 mg/dL (RR 40–
230). The patient was diagnosed with lupus induced by 
infliximab, and infliximab was suspended. Anti-inflix-
imab antibodies were not available at this time in our hos-
pital. The remaining investigation revealed a normal re-
nal function (estimated glomerular filtration rate using 
the Chronic Kidney Disease Epidemiology Collaboration 
[CKD-EPI] of 104 mL/min/1.73 m 2 ) without any change 
in urinary sediment analysis (including proteinuria and 
hematuria). There were no signs of serositis, oral ulcers, 
photosensitivity, blood disorders (leukopenia, lympho-
penia, thrombocytopenia, or hemolytic anemia), neuro-
logic disorder, or rash (malar or discoid). The clinical pre-
sentation was not compatible with other pathologies pre-
senting with symmetrical polyarthralgia because of the 
specified time frame of its presentation. In fact, the pa-
tient denied other symptoms suggestive of rheumatoid 
arthritis (early morning joint stiffness, synovitis of meta-
carpophalangeal joints, proximal interphalangeal or wrist 
joints, and subcutaneous nodules) or seronegative arthri-
tis, including IBD-associated arthritis (mainly asymmet-
rical, large joint oligoarticular involvement; possible spi-
nal involvement).
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 On re-evaluation of ulcerative proctitis at the time of 
suspension, the erythrocyte sedimentation rate was 25 
mm/h (first hour), C-reactive protein was 0.5 mg/dL, and 
endoscopically, a scarred mucosa with some atrophy and 
scarce mucus in the lower rectum was found. In a total 
colonoscopy, no other abnormalities were detected.
 Therapeutic Focus and Assessment 
 Following the diagnosis of infliximab-induced lupus, 
the patient suspended infliximab and started hydroxy-
chloroquine 400 mg daily. After 8 weeks, she experienced 
total remission of the symptoms.
 About 10 months after the discontinuation of inflix-
imab, the autoantibodies that were previously positive 
(ANA, anti-dsDNA, and anti-histone) were repeated 
and proved all negative, keeping only a low C3 (87). She 
also reported complete resolution of arthralgia and mal-
aise. Hydroxychloroquine and azathioprine were main-
tained.
 One year after the suspension of infliximab, the sig-
moidoscopy was repeated, showing a healed mucosa with 
some atrophy and scarce mucus in the lower rectum.
 Follow-Up and Outcomes 
 One year and 6 months after the suspension of inflix-
imab, the patient remains asymptomatic and shows no 
abnormalities in the blood tests (complete blood count, 
erythrocyte sedimentation rate, and C-reactive protein).
 Discussion 
 According to the SLICC criteria  [9] , the patient ful-
filled 3 immunological criteria for SLE that appeared after 
therapy with infliximab: high ANA, high anti-dsDNA, 
and reduced C3. The patient complained of polyarthral-
gia, but this was not objectified as polyarthritis and there-
fore not accomplishing the minimum of 1 clinical crite-
rion according to this classification. However, the SLICC 
criteria are established for the diagnosis of SLE, and no 
specific criteria or tests exist to establish the diagnosis of 
DIL, which has some distinguishing features, as previ-
ously stated. This is typically diagnosed in a patient taking 
a drug associated with DIL for at least 1 month and who 
presents with at least 1 clinical feature characteristic of 
SLE and a positive ANA  [4] . Our patient reported malaise 
and polyarthralgia 2.5 years after taking infliximab and 
fulfilled 3 immunological criteria. A spontaneous resolu-
tion of the clinical picture typically occurs within weeks 
and contributes to confirm the diagnosis  [4] . In our case, 
the clinical remission was verified 8 weeks after the sus-
pension, and the immunological remission 9 months 
thereafter, strongly supporting the definitive diagnosis of 
infliximab-induced lupus.
 The frequency, clinical, and serological characteristics 
of anti-TNF-induced lupus differ from classical DIL. The 
clinical presentation is characterized by arthralgia or 
polyarthritis, mucocutaneous manifestations, and, less 
frequently, serositis. Renal and neurological manifesta-
tions are extremely rare. The most frequent antibodies are 
ANA and anti-dsDNA, positive in 79 and 72% of the cas-
es, respectively. Anti-histone antibodies, a hallmark of 
DIL (procainamide or hydralazine), were only positive in 
17–57% of the patients  [6, 10] .
 Treating 500 patients with infliximab and following 
them up for 17 months the Mayo clinic reported only 3 
DIL cases  [11] . Older patients and dsDNA antibody levels 
 ≥ 9 U/mL (but not ANA titers  ≥ 1: 240) are risk factors for 
the development of ANA and lupus, while concomitant 
immunosuppressive therapy may have a protective effect 
 [12] .
 Due to the significant number of reported cases of 
adalimumab-induced lupus  [10] , we decided not to initi-
ate another anti-TNF until a new flare occurred, main-
taining hydroxychloroquine and azathioprine. In 54 re-
ported cases of autoimmune diseases induced by anti-
TNF, therapy reintroduction resulted in 69% relapses 
when the same biological was used and in 29% when 
starting another anti-TNF  [10] . However, it is important 
to stress that the duration of the follow-up was not de-
tailed, which can underestimate the data found. In the 
context of IBD, 8 patients were treated with a second an-
ti-TNF agent, of whom 2 patients developed recurrent 
DIL following 3 months of therapy (25% relapse); the re-
maining patients remained well after a median follow-up 
of 5 months  [13] .
 The experience with golimumab is still very limited 
compared to infliximab or adalimumab. There is a report 
of a subacute cutaneous lupus erythematosus exacerba-
tion with golimumab  [14] . To our knowledge, there are 
no cases of golimumab-induced lupus to date, and there-
fore, golimumab would be the authors’ choice in case of 
a new flare of ulcerative colitis in the patient presented 
herein.
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